William Schief, PhD

Department of Immunology and Microbiology
California Campus

Scripps Research Joint Appointments

Faculty, Graduate Program

Other Joint Appointments

The Ragon Institute of MGH, MIT and Harvard (Associate Member)
IAVI Neutralizing Antibody Center, The Scripps Research Institute


Ph.D. (Physics), 1999
B.S. (Applied Mathematics), Yale University, 1989

Professional Experience

2011-2014 Associate Professor of Immunology, Immunology and Microbial Science (IMS), Scripps Research

Selected References

All Publications

Duan, H., Chen, X., Boyington, J. C., Cheng, C., Zhang, Y., Jafari, A. J., Stephens, T., Tsybovsky, Y., Kalyuzhniy, O., Zhao, P., Menis, S., Nason, M. C., et al. Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. (2018). Immunity, 49(2), 301-311.

Crooks, E. T., Grimley, S. L., Cully, M., Osawa, K., Dekkers, G., Saunders, K., Ramisch, S., Menis, S., Schief, W. R., Doria-Rose, N., Haynes, B., Murrell, B., et al. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. (2018). PLoS Pathogens, 14. PMCID: PMC5951585.

Abbott, R. K., Lee, J. H., Menis, S., Skog, P., Rossi, M., Ota, T., Kulp, D. W., Bhullar, D., Kalyuzhniy, O., Havenar-Daughton, C., Schief, W. R., Nemazee, D., et al. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. (2018). Immunity, 48(1), 133-146. PMCID: PMC5773359.

Adolf-Bryfogle, J., Kalyuzhniy, O., Kubitz, M., Weitzner, B. D., Hu, X., Adachi, Y., Schief, W. R. & Dunbrack, R. L. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design. (2018). PLoS Computational Biology, 14. PMCID: PMC5942852.

Havenar-Daughton, C., Sarkar, A., Kulp, D. W., Toy, L., Hu, X., Deresa, I., Kalyuzhniy, O., Kaushik, K., Upadhyay, A. A., Menis, S., Landais, E., Cao, L., et al. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. (2018). Science Translational Medicine, 10.

Crooks, E. T., Osawa, K., Tong, T., Grimley, S. L., Dai, Y. D., Whalen, R. G., Kulp, D. W., Menis, S., Schief, W. R. & Binley, J. M. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. (2017). Virology, 505, 193.

Pauthner, M., Havenar-Daughton, C., Sok, D., Nkolola, J. P., Bastidas, R., Boopathy, A. V., Carnathan, D. G., Chandrashekar, A., Cirelli, K. M., Cottrell, C. A., Eroshkin, A. M., Guenaga, J., et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. (2017). Immunity, 46(6), 1073-1088. PMCID: PMC5483234.

Virnik, K., Nesti, E., Dail, C., Hockenbury, M., Ni, Y. S., Felber, B. K., Schief, W. R. & Berkower, I. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. (2017). Vaccine, 35(24), 3272-3278.

Cao, L., Diedrich, J. K., Kulp, D. W., Pauthner, M., He, L., Park, S. K. R., Sok, D., Su, C. Y., Delahunty, C. M., Menis, S., Andrabi, R., Guenaga, J., et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. (2017). Nature Communications, 8.

Irimia, A., Serra, A. M., Sarkar, A., Jacak, R., Kalyuzhniy, O., Sok, D., Saye-Francisco, K. L., Schiffner, T., Tingle, R., Kubitz, M., Adachi, Y., Stanfield, R. L., et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. (2017). PLoS Pathogens, 13. PMCID: PMC5338832.